Scott Gottlieb Quotes
The first nation to develop a vaccine for Covid-19 could have an economic advantage as well as a tremendous public-health achievement. Doses will be limited initially as suppliers ramp up, and a country will focus on inoculating most of its own population first.
Gottlieb, Scott. "The Geopolitics of a Covid-19 Vaccine." The Wall Street Journal, 2020.
The U. S. supply of flu shots was very erratic and most of the flu vaccine that we used was then manufactured abroad. In the George W. Bush administration, vaccine production had become a political issue of legal liability and who would order what was needed.
There was U. S. criticism that the same technology could be used to make biological weapons. In addition there are continuing intellectual property disputes with international pharmaceutical companies who believe their patent rights preclude Cuba from making some of the vaccines.
Scott Gottlieb is an American physician and investor who served as the 23rd commissioner of the Food and Drug Administration (FDA) from 2017 until April 2019. He is presently a resident fellow at the conservative think tank the American Enterprise Institute (AEI), a partner at the venture capital firm New Enterprise Associates (NEA), a member of the board of directors of drug maker Pfizer, Inc, a member of the board of directors of Illumina, Inc., and a contributor to the cable financial news network CNBC. Before becoming FDA commissioner, he was a clinical assistant professor at New York University School of Medicine, the FDA deputy commissioner for medical and scientific affairs, a venture partner with New Enterprise Associates, a member of the policy board of the Leukemia & Lymphoma Society, a senior official at the Centers for Medicare and Medicaid Services, and a member of the Federal Health Information Technology Policy Committee, which advises the United States Department of Health and Human Services on healthcare information technology. He was previously a resident fellow at AEI from 2007 to 2017 prior to joining the FDA as commissioner in May 2017.
